#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	2916	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2907	295.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1824	1824	C	414	C	372	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4836	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4205	344.5	0	.	n	.	0	T695C	SNP	695	695	T	1355	1355	C	345	C	309	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4836	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4205	344.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1997	1997	A	385	A	365	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4836	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4205	344.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2631	2631	C	466	C	420	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4836	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4205	344.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2705	2705	A	494	A	448	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4836	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4205	344.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3257	3257	C	469	C,A,T	402,2,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	804	folP	852	852	100.0	folP.l15.c4.ctg.1	1928	124.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1188	1190	AGC	164;166;167	A,G;G,C;C,A	147,1;153,1;151,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1336	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3885	102.8	1	SNP	p	S91F	0	.	.	271	273	TCC	846	848	TCC	114;114;116	T;C;C	110;111;109	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1336	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3885	102.8	1	SNP	p	D95N	0	.	.	283	285	GAC	858	860	GAC	111;111;112	G;A;C	107;108;107	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1336	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	3885	102.8	1	SNP	p	D95G	0	.	.	283	285	GAC	858	860	GAC	111;111;112	G;A;C	107;108;107	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	M16I	NONSYN	46	48	ATG	591	593	ATT	77;77;76	A;T;T,A	63;64;62,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	D40A	NONSYN	118	120	GAC	663	665	GCC	60;60;61	G;C;C	58;57;59	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	R44H	NONSYN	130	132	CGC	675	677	CAC	60;60;61	C;A;C	59;59;58	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	I73M	NONSYN	217	219	ATC	762	764	ATG	60;60;60	A;T;G	60;56;59	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	A74S	NONSYN	220	222	GCG	765	767	TCG	60;60;60	T;C;G	58;59;60	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	Q75K	NONSYN	223	225	CAA	768	770	AAA	60;60;60	A;A;A	59;59;59	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	A77T	NONSYN	229	231	GCC	774	776	ACG	60;60;61	A;C;G	59;60;59	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	.	MULTIPLE	233	234	CA	778	780	AAA	61;61;61	A;A;A,G	60;59;59,1	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	D79N	NONSYN	235	237	GAT	783	785	AAT	61;61;61	A;A;T	59;59;59	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	G83Q	NONSYN	247	249	GGG	795	797	CAA	61;62;62	C;A;A	59;60;61	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	H90R	NONSYN	268	270	CAC	816	818	CGT	63;63;63	C;G;T	60;61;60	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	N110S	NONSYN	328	330	AAC	876	878	AGC	61;61;61	A;G;C	51;50;51	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	V143F	NONSYN	427	429	GTT	975	977	TTT	49;49;48	T;T;T	37;40;39	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	A154S	NONSYN	460	462	GCT	1008	1010	TCG	41;39;38	T;C;G	35;36;37	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	D155G	NONSYN	463	465	GAC	1011	1013	GGT	38;38;37	G;G;T	35;36;35	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	T161M	NONSYN	481	483	ACG	1029	1031	ATG	35;35;34	A;T;G	34;34;33	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	T169M	NONSYN	505	507	ACG	1053	1055	ATG	32;32;32	A;T;G	30;32;31	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	F178L	NONSYN	532	534	TTC	1080	1082	CTC	32;32;32	C;T;C	31;31;32	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	S183N	NONSYN	547	549	AGT	1095	1097	AAT	31;31;31	A;A;T	31;31;29	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	G195E	NONSYN	583	585	GGG	1131	1133	GAA	31;31;31	G;A;A	30;29;30	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	0	.	p	.	0	C206Q	NONSYN	616	618	TGC	1164	1166	CAG	22;21;20	C,A;A;G	21,1;20;20	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	182	mtrR	633	633	91.19	mtrR.l6.c30.ctg.1	1596	33.5	1	SNP	p	G45D	0	.	.	133	135	GGC	678	680	GGC	61;58;59	G;G;C	58;57;58	mtrR.WHO_Z_01455:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1462	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3549	123.4	1	SNP	p	D86N	0	.	.	256	258	GAC	848	850	GAC	151;150;151	G;A,G,C;C	138;130,1,1;136	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1462	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3549	123.4	1	SNP	p	S87W	0	.	.	259	261	AGT	851	853	AGT	152;152;152	A,C;G;T,G	132,2;140;136,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1462	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3549	123.4	1	SNP	p	S87I	0	.	.	259	261	AGT	851	853	AGT	152;152;152	A,C;G;T,G	132,2;140;136,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1462	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3549	123.4	1	SNP	p	S87R	0	.	.	259	261	AGT	851	853	AGT	152;152;152	A,C;G;T,G	132,2;140;136,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1462	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3549	123.4	1	SNP	p	S88P	0	.	.	262	264	TCC	854	856	TCC	153;152;151	T,G;C;C	134,1;139;144	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1220	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3358	108.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1962	1964	GGC	144;142;142	G;G;C	128;128;124	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1506	1508	GCA	148;146;146	G;C;A	137;134;135	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1509	1511	ATC	144;144;145	A;T;C	133;129;133	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1521	1523	GTG	150;149;149	G;T;G,T	135;134;132,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1521	1523	GTG	150;149;149	G;T;G,T	135;134;132,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2025	2027	ACC	102;102;101	A;C;C,T	97;96;87,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2079	2081	GCG	115;112;110	G;C;G	101;93;94	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2079	2081	GCG	115;112;110	G;C;G	101;93;94	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2202	2204	GGC	99;99;100	G;G;C	94;91;92	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2211	2213	GGC	100;100;100	G,A,C;G;C	92,1,1;90;92	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	968	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2964	97.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2229	2231	CCG	99;98;98	C;C;G	89;93;90	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1242	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3657	101.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	602	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2483	72.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	928	928	C	100	C,T	87,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	286	91.03	porB1a.l6.c17.ctg.1	1394	18.1	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1133	1135	AAT	5;5;5	A;A;T	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	286	91.03	porB1a.l6.c17.ctg.1	1394	18.1	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1136	1138	AAT	5;5;5	A;A;T	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	286	91.03	porB1a.l6.c17.ctg.1	1394	18.1	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1160	1162	GCA	5;5;5	G;C;A	4;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	286	91.03	porB1a.l6.c17.ctg.1	1394	18.1	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1183	1185	GTA	4;4;4	G;T;A	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	88	porB1a	984	286	91.03	porB1a.l6.c17.ctg.1	1394	18.1	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1192	1192	A	4	A	4	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	674	porB1b	1038	1038	99.42	porB1b.l15.c4.ctg.1	1932	102.7	0	.	p	.	0	I45V	NONSYN	133	135	ATT	730	732	GTT	154;154;155	G;T;T	146;142;147	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	674	porB1b	1038	1038	99.42	porB1b.l15.c4.ctg.1	1932	102.7	0	.	p	.	0	I75V	NONSYN	223	225	ATT	820	822	GTT	154;153;153	G,T;T;T,G	134,1;125;130,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	674	porB1b	1038	1038	99.42	porB1b.l15.c4.ctg.1	1932	102.7	0	.	p	.	0	S89T	NONSYN	265	267	AGC	862	864	ACC	160;162;160	A;C;C	134;137;141	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	674	porB1b	1038	1038	99.42	porB1b.l15.c4.ctg.1	1932	102.7	0	.	p	.	0	I98V	NONSYN	292	294	ATC	889	891	GTC	157;155;155	G;T;C,A	139;137;137,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	674	porB1b	1038	1038	99.42	porB1b.l15.c4.ctg.1	1932	102.7	0	.	p	.	0	S217G	NONSYN	649	651	AGT	1246	1248	GGT	126;125;123	G;G;T,G	116;115;111,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	674	porB1b	1038	1038	99.42	porB1b.l15.c4.ctg.1	1932	102.7	1	SNP	p	G120K	1	.	.	358	360	AAG	955	957	AAG	155;154;154	A;A;G	142;139;138	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	674	porB1b	1038	1038	99.42	porB1b.l15.c4.ctg.1	1932	102.7	1	SNP	p	N121D	0	.	.	361	363	AAC	958	960	AAC	154;154;155	A,G;A;C	137,1;137;138	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	674	porB1b	1038	1038	99.42	porB1b.l15.c4.ctg.1	1932	102.7	1	SNP	p	A121N	1	.	.	361	363	AAC	958	960	AAC	154;154;155	A,G;A;C	137,1;137;138	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1656	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5704	86.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2383	2385	AAT	89;89;88	A,G;A;T	79,1;81;79	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	228	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1646	41.4	1	SNP	p	V57M	1	.	.	169	171	ATG	859	861	ATG	79;80;81	A,G;T,G;G	74,1;74,1;74	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
